Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14129
Abstract: Essentials Risk stratification for venous thromboembolism (VTE) in patients with brain tumors is challenging. Patients with IDH1 wildtype and high podoplanin expression have a 6‐month VTE risk of 18.2%. Patients with IDH1 mutation and no… read more here.
Keywords: mutation podoplanin; podoplanin; idh1 mutation; podoplanin expression ... See more keywords
Podoplanin expression in oral potentially malignant disorders and oral squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical and Experimental Dentistry"
DOI: 10.4317/jced.54213
Abstract: Background Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is specifically expressed in lymphatic endothelial cells. Studies have shown that assessment of podoplanin expression in the epithelial cells can be used to predict the… read more here.
Keywords: cell carcinoma; squamous cell; expression; podoplanin expression ... See more keywords